Replies to post #130979 on Biotech Values

[biomaven0]

Rather, I anticipate that new drugs such as Ponatinib will bear the brunt of the storm.

Ponatinib is extremely unlikely to be the poster-child for any such storm. For patients with a T315I mutation you would be telling them to go away and die, or more likely go have a bone marrow transplant (which is $200k upfront assuming everything goes smoothly, and maybe a million or more when it doesn't). As Yogi Berra might say, insurance companies may be dumb, but they aren't stupid.

Peter